US FDA to improve communication on risk:benefit issues
This article was originally published in SRA
The US Food and Drug Administration has developed a Strategic Plan for Risk Communication in its effort to provide healthcare professionals and consumers with more meaningful information about the benefits and risks of regulated products, ie drugs, medical devices, food and tobacco1,2.
You may also be interested in...
The European Medicines Agency is developing a strategy to ensure that women have sufficient information to make informed choices about taking medicines during pregnancy and breastfeeding.
A first-of-its-kind collaborative study has found that real-world and natural history data are comparable to placebo data from clinical trials in Duchenne muscular dystrophy.
An EU group has listed several ambitious projects to help EU regulators realize their cherished vision of using big data capabilities to support innovation and public health. But these proposals may take a backseat as COVID-19-related challenges continue.